Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | RRM2 | P31350 | 2/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694416 | 0.85 | MAOA (0.43) | MAPTNOS3NOS2GAANAMPT | |
| SCHEMBL19981909 | 0.82 | ADRA2A (0.40) | MAPTNOS3NOS2GAAADRA2A | |
| SCHEMBL22175094 | 0.81 | MAPT (0.38) | MAPTNOS3NOS2GAAADRA2A | |
| SCHEMBL18779716 | 0.79 | KCNH3 (0.40) | NOS3NOS2GAAADRA2AADRA2B | |
| SCHEMBL20037762 | 0.79 | MAPT (0.43) | MAPTGAASTK17AKDM4ETAAR1 | |
| SCHEMBL2483964 | 0.79 | KCNH3 (0.48) | MAPTNOS3NOS2GAAALPL | |
| SCHEMBL28820864 | 0.79 | NOS3 (0.42) | MAPTNOS3NOS2GAAADRA2A | |
| SCHEMBL16963191 | 0.79 | HRH3 (0.47) | NOS3NOS2GAAHRH3 | |
| SCHEMBL2487033 | 0.79 | ADRA2A (0.53) | MAPTNOS3NOS2ADRA2AADRA2B | |
| SCHEMBL20878669 | 0.78 | MTNR1A (0.48) | NAMPTGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| US-20210214339-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2019079375-A1 | PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAPT 3636/4885NOS3 3916/4885NOS2 3764/4885 |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | MAPT 1313/4885NOS3 3191/4885NOS2 2698/4885 |
| US-20210214339-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | MAPT 1313/4885NOS3 3191/4885NOS2 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.